Strong Demand for Wegovy and Ozempic: Novo Nordisk Q3 Sales Surge by 33%, 47% Operating Profit Growth
Novo Nordisk, Europe’s most valuable company in 2023, announced on Friday a significant upward revision of its full-year sales and operating profit outlook, surpassing market
